MedTrace Logo

Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease

NCT02779946 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 216

Last updated 2017-06-16

No results posted yet for this study

Summary

Background: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome, which is one of the major risk factors of coronary heart disease (CHD). CHD is the most important manifestation of atherosclerosis, because of its immense morbidity and mortality. Transient elastography (TE, Fibroscan®) including the currently developed controlled attenuation parameter (CAP) is a non-invasive method for evaluation of liver fibrosis and steatosis, which is already implemented in routine care of patients with NAFLD. Hypothesis: The use of TE with CAP as screening for NAFLD might be an easy tool for risk assessment for CHD. Methods: Patients scheduled for routine coronary angiography will be screened for manifestation of NAFLD by TE including CAP, conventional ultrasound, clinical and laboratory parameters. Patients will be stratified for the presence of CHD based on the angiography results and correlation analysis with liver fat content will be performed. NFALD screening will be validated in a subgroup by MR-based measurements.

Conditions

  • Coronary Disease
  • Non-alcoholic Fatty Liver Disease
  • Elasticity Imaging Techniques

Interventions

DEVICE

Fibro Scan

GENETIC

PNPLA3

Sponsors & Collaborators

  • Universitätsklinikum Leipzig

    collaborator OTHER

  • University of Leipzig

    lead OTHER

Principal Investigators

  • Sebastian Beer, MD · Leipzig University Medical Center, IFB AdiposityDiseases

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-03-31
Completion
2017-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02779946 on ClinicalTrials.gov